Skip to main content

Lorenzo REFOLO

Lorenzo Refolo
Title: Chief, Translational Research Branch, Division of Neuroscience
Office(s): Division of Neuroscience (DN)
Phone Number: 301-594-7576
Email Address: refolol@mail.nih.gov

Biography

Dr. Refolo is the Director for Alzheimer ’s Disease Drug Discovery and Development at the National Institute on Aging (NIA). He received his Ph.D. in Molecular Genetics from the Rutgers University School of Medicine and, postdoctoral training at the Laboratory of Neurobiology at Rockefeller University and, Department of Psychiatry at Mount Sinai School of Medicine. Following his postdoctoral training Dr. Refolo held positions as Assistant Professor at Mount Sinai School of Medicine, New York, Associate Consultant and Assistant Professor at the Mayo Clinic, Jacksonville, Florida and, Research Scientist at the Nathan Kline Institute for Psychiatric Research at New York University. His research focused for the most part on the molecular-cell biology of Alzheimer’s disease.

After leaving academia Dr. Refolo was the Scientific Director at the Institute for the Study of Aging where he created and managed a large portfolio of Alzheimer’s drug discovery programs. In 2005 Dr. Refolo joined the NIH as a Program Director at the National Institute of Neurological Disorders and Stroke, managing a portfolio of basic, clinical, and translational research that was focused on neurodegenerative diseases. He has been at the NIA since 2010, developing and managing a diverse portfolio of translational research programs.

Research Interests/Portfolio

  • Alzheimer’s Drug-Development Program (U01 cooperative agreement)
  • Drug Discovery for Nervous System Disorders (R01/R21)/Preclinical drug discovery and development of novel/repurposed compounds for prevention and treatment of MCI, AD, and other dementias of aging
  • Blueprint Neurotherapeutics Network (BPN): Small molecule drug discovery and development of disorders of the nervous system (UG3/UH3 phased cooperative agreement)
  • Model Organism Development and Evaluation for Late-Onset AD (MODEL-AD) Initiative/Alzheimer’s Disease Center for Disease Model Resources (U54 cooperative agreement)
  • Centers for Discovery of New Medicines (CDNM)/Alzheimer Centers for Discovery of New Medicines (U54 cooperative agreement)